Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Revitalizing equine metabolism: how SHBG improves mitochondrial function and reduces inflammation.

Bourebaba N., Domagała J., Bourebaba L.

Animal Study on Type 2 Diabetes, Chronic Inflammation, published in BMC Vet Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
BMC Vet Res (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41121214
PMCID
PMC12539183
DOI
10.1186/s12917-025-05033-y
Citations
1

Abstract (original English)

BACKGROUND: Equine metabolic syndrome (EMS) is associated with chronic low-grade inflammation, disruptions in mitochondrial dynamics and function, and an increased risk of developing laminitis. Recent research has highlighted that reduced levels of sex hormone-binding globulin (SHBG) in the bloodstream are linked to higher susceptibility to obesity, insulin resistance, and diabetes, potentially contributing to broader metabolic imbalances. This study aimed to evaluate whether exogenously administered SHBG could protect adipose-derived stem cells from horses affected by EMS (EqASCEMS) against mitochondrial dysfunction and inflammatory activation. RESULTS: Following treatment with 50 nM of SHBG, analyses were conducted to assess cell viability, mitochondrial metabolism and dynamics, as well as the expression of inflammatory and anti-inflammatory markers. Results showed that SHBG significantly enhanced mitochondrial flexibility, as indicated by the upregulation of MFN-1, PARKIN, and PINK genes. SHBG also positively influenced the expression of genes related to mitoribosomes and the mitochondrial oxidative phosphorylation (OXPHOS) system. In addition, SHBG treatment markedly reduced EMS-induced inflammation by decreasing pro-inflammatory cytokines such as IL-1β as well as IL-6 and boosting anti-inflammatory cytokines gene expression (IL-10 and IL-13). CONCLUSION: Our findings sugge

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMitochondriaInflammationHorsesSex Hormone-Binding GlobulinMetabolic SyndromeHorse DiseasesCytokinesCell SurvivalStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research